A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00037089|
Recruitment Status : Unknown
Verified January 2005 by Edelman, Martin, M.D..
Recruitment status was: Active, not recruiting
First Posted : May 15, 2002
Last Update Posted : June 24, 2005
This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to:
- Determine how well a combination of taxol, UFT, and leucovorin work in these patients,
- Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs.
- Identify the side effects of this drug combination.
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Neoplasm||Drug: UFT (Tegafur/Uracil)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00037089
|United States, Maryland|
|University of Maryland Cancer Center|
|Baltimore, Maryland, United States, 21201|